Belrestotug

DB19066InvestigationalProtein Based Therapies

Belrestotug is under investigation in clinical trial NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/metastatic Non-small-cell Lung Cancer).

Mechanism: Pharmacologically active on T-cell immunoreceptor with Ig and ITIM domains
Curator reviewed
Also known as: CLONE 31282 · Immunoglobulin g1, anti-(human receptor tigit) (human monoclonal eos884448 .gamma.1-chain), disulfide with human monoclonal eos884448 .kappa.-chain, dimer
Code names: EOS-448 · EOS-884448 · GSK-4428859A · WB-2127

Resolves to

Compound

UNII59HAW3EQ4CCAS2574438-65-4

Targets

Q495A1TIGIT

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Belrestotug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account